At what age can one join polivy studies?

Polivy Clinical Trial Age Requirements

Polivy (polatuzumab vedotin-piiq), used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has ongoing clinical trials with eligibility criteria set by each study's protocol. Age minimums vary, but most require participants to be 18 years or older.[1]

Common Age Limits in Active Polivy Trials

• Adults only (18+): The majority of trials, like NCT03671018 (Phase 2 for DLBCL) and NCT03366272 (Phase 3 POLARIX trial), limit enrollment to adults aged 18-80 or similar upper limits based on fitness.[1][2]
  
• Pediatric trials: No active Polivy trials target patients under 18. A completed Phase 1 pediatric study (NCT03091762) enrolled ages 12-18 with relapsed/refractory B-cell lymphomas, but it is no longer recruiting.[3]
  
• Upper age caps: Often 75-80 years, excluding frail elderly due to toxicity risks like neuropathy or cytopenias.[1]
  
  

Why Age Restrictions Exist

Trials prioritize adults because DLBCL is rare in children (incidence peaks after 50). Pediatric safety data is limited; Polivy lacks FDA approval for under-18s.[4] Sponsors like Genentech/Roche design protocols to match disease demographics and drug tolerability.

How to Check Specific Trials

Search ClinicalTrials.gov for "polivy" or "polatuzumab vedotin" and filter by location/recruitment status. Criteria like ECOG performance status (0-2) often pair with age limits. Contact study coordinators for exceptions, such as compassionate use.[1]

Related Concerns for Younger Patients

Patients under 18 with DLBCL typically use pediatric regimens like R-CHOP alternatives. No biosimilars or generics affect age rules, as Polivy is patented until ~2031 (check DrugPatentWatch.com for updates).[5]

Sources
[1]: ClinicalTrials.gov - Polivy Trials
[2]: POLARIX Trial (NCT03366272)
[3]: Pediatric Polivy Trial (NCT03091762)
[4]: FDA Label - Polivy
[5]: DrugPatentWatch.com - Polivy Patents